유방암 진단 시장 : 전략적 인사이트 및 예측(2026-2035년)

The Breast Cancer Diagnostics Market is expected to grow at a CAGR of 5.5% from a market value of USD 16.0 billion in 2026 to USD 25.9 billion in 2035.

The breast cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward integrated diagnostic pathways and precision oncology. The market's evolution is characterized by the growing recognition that treatment decisions increasingly depend on comprehensive molecular characterization rather than histological evaluation alone. The convergence of advanced imaging systems, digital pathology, next-generation sequencing, and artificial intelligence is enabling more accurate lesion detection, pathological confirmation, and predictive biomarker identification. Healthcare systems are expanding organized screening programs because early-stage detection substantially improves clinical outcomes and treatment options. The rising adoption of precision oncology is increasing demand for validated biomarker assays capable of identifying HER2 expression, hormone receptor status, BRCA mutations, PIK3CA alterations, and other clinically relevant genomic markers. Diagnostic manufacturers are expanding product portfolios through automation, digital integration, and companion diagnostic development to support individualized treatment pathways. The market is witnessing significant investment in AI-enabled imaging solutions, liquid biopsy technologies, and multiplex molecular assays, positioning breast cancer diagnostics as an essential foundation of personalized cancer care across global healthcare systems.

Market Drivers

• The increasing adoption of precision oncology represents the primary driver for the breast cancer diagnostics market. Precision oncology increasingly relies on molecular characterization to match patients with targeted therapies, making biomarker testing an essential component of breast cancer management. Clinical practice is increasingly incorporating genomic profiling because therapeutic eligibility depends on accurate identification of predictive biomarkers such as HER2, hormone receptors, BRCA1/2, and PIK3CA alterations. This dependency raises demand for highly sensitive molecular assays that deliver reproducible results across diverse clinical settings. Diagnostic manufacturers are expanding companion diagnostic portfolios through collaborations with pharmaceutical companies developing targeted therapies, resulting in sustained growth in biomarker-based diagnostic utilization. Organized screening programs are further accelerating market growth by increasing diagnostic volumes. Population-based breast cancer screening remains a fundamental mechanism for identifying disease before symptom onset. National healthcare systems are continuing to expand screening participation because early-stage detection substantially improves clinical outcomes and treatment options. Increased identification of suspicious lesions creates sustained demand for diagnostic imaging, biopsy procedures, pathology assessment, and confirmatory molecular testing. Healthcare providers are therefore investing in advanced mammography systems, breast tomosynthesis, breast MRI, ultrasound, and AI-assisted image interpretation to manage growing patient volumes while maintaining diagnostic accuracy. Artificial intelligence integration is improving diagnostic efficiency and workflow optimization. Growing imaging workloads create operational pressure for radiology departments that must maintain diagnostic quality while addressing workforce limitations. AI-enabled image analysis is increasingly assisting radiologists by prioritizing suspicious findings, improving lesion detection, and supporting workflow optimization. This technological integration reduces interpretation variability while enabling clinicians to focus on complex diagnostic cases. Medical imaging companies are continuously developing software capable of integrating with existing picture archiving and communication systems, encouraging broader institutional adoption. Expanding molecular testing is supporting personalized clinical decision-making through comprehensive disease characterization. Breast cancer encompasses biologically diverse disease subtypes that require different therapeutic strategies. Diagnostic laboratories are increasingly incorporating genomic assays because comprehensive molecular profiling improves risk stratification and prognosis assessment beyond conventional pathology. Growing availability of targeted therapies reinforces the clinical importance of accurate biomarker detection, encouraging healthcare providers to standardize molecular testing across patient care pathways.

Market Restraints

• High acquisition and maintenance costs associated with advanced imaging systems, molecular diagnostic platforms, and digital pathology infrastructure continue to limit adoption among resource-constrained healthcare providers. The substantial capital investment required for advanced technologies creates barriers for smaller facilities and practices. Variability in reimbursement policies for genomic testing and advanced molecular diagnostics reduces testing accessibility and influences healthcare provider purchasing decisions across several regions. Inconsistent coverage policies limit patient access to advanced testing options. Regulatory requirements for analytical validation, clinical evidence generation, software verification, and post-market surveillance increase product development timelines and commercialization costs for diagnostic manufacturers. The rigorous approval processes create challenges for smaller diagnostic companies. Shortages of specialized pathology and molecular diagnostics expertise constrain efficient utilization of advanced diagnostic platforms, limiting scalability in many healthcare settings.

Technology and Segment Insights

• The technology landscape is characterized by the growing importance of integrated diagnostic workflows. Demand continues to shift toward integrated diagnostic pathways because treatment decisions increasingly depend on comprehensive molecular characterization rather than histological evaluation alone. This transition is expanding the role of NGS, digital pathology, AI-assisted image interpretation, multiplex immunohistochemistry, and companion diagnostics across oncology practices. Hospitals and cancer centers are consequently adopting multimodal diagnostic workflows that combine radiological, pathological, and genomic information. Mammography remains the primary screening modality, with digital breast tomosynthesis gaining adoption for improved lesion detection. Breast ultrasound and MRI serve as complementary imaging tools for diagnostic confirmation and high-risk screening. Biopsy procedures provide tissue for pathological and molecular evaluation. The segment analysis reveals that reagents and consumables represent the recurring component of the market because every diagnostic workflow depends on assay-specific kits, antibodies, probes, staining reagents, sequencing reagents, and quality control materials. Demand is increasing as healthcare providers perform larger numbers of screening, IHC, FISH, PCR, and NGS tests across both centralized and decentralized laboratory settings. Screening and early detection constitute a fundamental application segment because clinical outcomes improve substantially when breast cancer is identified before disease progression. Organized screening programs are increasing the number of women undergoing mammography and supplemental imaging, creating sustained demand for confirmatory diagnostic procedures. Hormone receptor testing and HER2 testing remain essential for therapeutic selection, with genetic marker testing expanding for hereditary risk assessment and treatment guidance. Hospitals remain the primary end users because they provide integrated diagnostic, surgical, pathological, and oncological services within a coordinated clinical environment. Diagnostic laboratories and cancer centers are expanding specialized testing services to support precision oncology programs. The integration of AI is becoming increasingly important across imaging and pathology workflows, with AI-enabled solutions assisting radiologists and pathologists in lesion detection, biomarker quantification, and workflow prioritization.

Competitive and Strategic Outlook

• The competitive landscape features established imaging and diagnostic companies alongside specialized molecular testing and precision oncology providers. Hologic differentiates itself through its exclusive focus on women's health, supported by a comprehensive portfolio of breast imaging, biopsy, and diagnostic technologies, continuing to expand AI-enabled mammography and breast health solutions. Roche maintains a leading position in precision oncology by combining molecular diagnostics, tissue diagnostics, and companion diagnostic development with its pharmaceutical portfolio, continuing to invest in biomarker-driven diagnostics that support personalized breast cancer treatment. Siemens Healthineers leverages advanced imaging, AI, and digital healthcare platforms to strengthen breast cancer diagnostics, continuing to enhance workflow automation and image quality. GE HealthCare focuses on intelligent imaging solutions that integrate AI, digital workflow optimization, and advanced visualization technologies, with breast imaging innovations supporting earlier lesion detection. Philips differentiates itself through connected care and integrated diagnostic ecosystems that combine imaging technologies with digital informatics. Fujifilm combines digital imaging expertise with advanced mammography technologies to support breast cancer screening and diagnosis. NeoGenomics specializes in oncology-focused laboratory services and comprehensive molecular testing for precision medicine. Illumina remains a global leader in NGS technologies that enable comprehensive genomic profiling in oncology. Companies are pursuing product portfolio expansion through innovation in AI-enabled imaging, digital pathology, liquid biopsy, and companion diagnostic technologies. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include Perimeter Medical Imaging AI's Claire OCT System receiving FDA premarket approval as the first AI-enabled imaging device approved in the US for intraoperative assessment of breast cancer margins. DeepHealth launched Breast Suite, bringing together AI-powered breast cancer detection, breast density assessment, and risk assessment technologies. Hologic presented new data on its AI-powered mammography technology at the Society of Breast Imaging Annual Symposium. GE HealthCare launched Invenia ABUS Premium, an AI-driven 3D breast ultrasound for early cancer detection in dense breasts. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The breast cancer diagnostics market is positioned for sustained growth driven by the convergence of organized screening programs, precision oncology adoption, and technological innovation. The transition from standalone detection technologies toward integrated precision oncology platforms represents a fundamental shift in breast cancer management. While challenges related to high costs, reimbursement variability, and regulatory complexity persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with breast cancer diagnostics evolving into an essential foundation of personalized cancer care, supporting early detection, accurate diagnosis, therapeutic selection, and longitudinal disease monitoring across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Breast Cancer Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Breast Cancer Overview
• 3.3 Disease Classification
• 3.4 Disease Burden & Unmet Clinical Needs
• 3.5 Epidemiology Analysis
  • 3.5.1 Disease Prevalence
  • 3.5.2 Incidence Analysis
  • 3.5.3 Diagnosed Patient Population
  • 3.5.4 Screening-Eligible Population
• 3.6 Patient Journey Analysis
• 3.7 Breast Cancer Diagnostic Pathway
• 3.8 Industry Evolution
• 3.9 Key Market Trends
• 3.10 Historical Market Size Analysis (2021-2025)
• 3.11 Market Forecast (2026-2035)

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Artificial Intelligence Integration in Breast Cancer Diagnostics
• 6.6 Digital Health Integration
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Breast Cancer Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology

9. Global Breast Cancer Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software & Services
• 9.2 By Technology
  • 9.2.1 Mammography
  • 9.2.2 Breast Ultrasound
  • 9.2.3 Magnetic Resonance Imaging (MRI)
  • 9.2.4 Computed Tomography (CT)
  • 9.2.5 Biopsy
  • 9.2.6 Other Diagnostic Technologies
• 9.3 By Biomarker
  • 9.3.1 Hormone Receptors
    • 9.3.1.1 Estrogen Receptor (ER)
    • 9.3.1.2 Progesterone Receptor (PR)
  • 9.3.3 Genetic Markers
  • 9.3.4 Other Biomarkers
• 9.4 By Sample Type
  • 9.4.1 Tissue
  • 9.4.2 Blood
  • 9.4.3 Fine Needle Aspiration Samples
  • 9.4.4 Other Sample Types
• 9.5 By Application
  • 9.5.1 Screening & Early Detection
  • 9.5.2 Diagnosis & Risk Management
  • 9.5.3 Prognosis
  • 9.5.4 Companion Diagnostics
  • 9.5.5 Disease and Treatment Monitoring
  • 9.5.6 Others
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Diagnostic Laboratories
  • 9.6.3 Cancer Centers
  • 9.6.4 Others

10. Global Breast Cancer Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Breast Cancer Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Hologic, Inc.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Roche Holding AG
• 13.3 Siemens AG
• 13.4 GE HealthCare Technologies Inc.
• 13.5 Koninklijke Philips N.V.
• 13.6 Fujifilm Holdings Corporation
• 13.7 NeoGenomics, Inc.
• 13.8 Illumina, Inc.
• 13.9 QIAGEN N.V.
• 13.10 Becton, Dickinson and Company

14. Global Breast Cancer Diagnostics Market Commercial Forecast Analysis

• 14.1 Mammography Systems
• 14.2 Digital Breast Tomosynthesis Systems
• 14.3 Breast Ultrasound Systems
• 14.4 Breast MRI Systems
• 14.5 Breast Biopsy Systems
• 14.6 Immunohistochemistry (IHC) Assays
• 14.7 HER2 ISH/FISH Assays
• 14.8 PCR-Based Breast Cancer Diagnostic Tests
• 14.9 Next-Generation Sequencing Panels
• 14.10 Gene Expression Profiling Assays
• 14.11 Liquid Biopsy Tests

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends